Neuland Laboratories Ltd

Neuland Laboratories Ltd Share Price Today: Live Updates & Key Insights

Get insights on Neuland Laboratories Ltd’s fundamentals, financials, shareholding, peer comparison, corporate actions & performance. Track key metrics, price trends & market sentiment for informed decisions. Explore all data at Motilal Oswal.

Neuland Laboratories Ltd Share Price Chart

Neuland Laboratories Ltd Fundamentals

Traded Volume: 49,218

Market Cap(Cr): 21,295

Avg Traded Price 16756.17

1 Year return 12.39%

Upper Circuit 17,089

Lower Circuit 16,475

P/E TTM 89.00

P/B Ratio 187.00

Traded Value(Cr) 8169.20

EPS TTM 187.177

Book value 187.177

Dividend 0.00%

Neuland Laboratories Ltd Share Price Performance

Shows the percentage change in stock price over different time periods

This section highlights Neuland Laboratories Ltd stock price performance across key timeframes, including 1-week, 1-month, 3-month, Year-To-Date (YTD), and 1-year returns. It provides insights into the Neuland Laboratories Ltd share price history, short-term movements, long-term trends, and overall investor sentiment

1W -3.63%

1M +0.94%

3M +21.22%

1Y +12.39%

YTD +16.96%

Neuland Laboratories Ltd Traded Volume Movement

Shows the trading volume over different time periods

This section highlights Neuland Laboratories Ltd daily and average traded volumes, offering insights into investor activity and market liquidity. Higher volumes than average often indicate rising interest, news impact, or shifting market sentiment

Yesterday 31544.00

Day Before Yesterday 22053.00

1W Avg 41163.80

1M Avg 66966.05

3M Avg 56169.00

Neuland Laboratories Ltd Technical Details

Neuland Laboratories Ltd technical indicators, such as support and resistance levels and pivot points, are calculated based on historical price and volume trends. These metrics help traders anticipate possible price movements and make informed trading decisions.

Support 1 16352

Support 2 16107

Support 3 15738

Pivot Point : 16721

Resistance 1 16966

Resistance 2 17335

Resistance 3 17580

Neuland Laboratories Ltd Corporate Actions

Neuland Laboratories Ltd corporate actions include dividends, bonus issues, stock splits, and key company updates that may affect share price and investor sentiment. This section provides timely details on past and upcoming actions, including ex-date, record date, and payout ratio - helping investors make informed decisions based on Neuland Laboratories Ltd’s capital allocation strategies.

All

Ex-Date 18-Jul-2025 Type D Description 12.00/share@120.00% Record Date 18-Jul-2025 Ratio 120.00

Ex-Date 12-Jul-2024 Type D Description 14.00/share@140.00% Record Date - Ratio 140.00

Ex-Date 11-Jul-2023 Type D Description 10.00/share@100.00% Record Date - Ratio 100.00

Ex-Date 14-Jul-2022 Type D Description 5.00/share@50.00% Record Date 15-Jul-2022 Ratio 50.00

Ex-Date 29-Jun-2021 Type D Description 3.00/share@30.00% Record Date - Ratio 30.00

Ex-Date 10-Nov-2020 Type D Description 2.00/share@20.00% Record Date 11-Nov-2020 Ratio 20.00

Ex-Date 18-Feb-2020 Type D Description 2.00/share@20.00% Record Date 20-Feb-2020 Ratio 20.00

Ex-Date 27-Jun-2019 Type D Description 1.20/share@12.00% Record Date - Ratio 12.00

Ex-Date 04-Aug-2016 Type D Description 2.00/share@20.00% Record Date - Ratio 20.00

Ex-Date 06-Aug-2015 Type D Description 1.50/share@15.00% Record Date - Ratio 15.00

Ex-Date 13-Aug-2014 Type R Description /share@4:25% Record Date 14-Aug-2014 Ratio 4:25

Ex-Date 16-Jun-2014 Type D Description 1.50/share@15.00% Record Date - Ratio 15.00

Ex-Date 16-Jun-2014 Type D Description 1.50/share@15.00% Record Date - Ratio 15.00

Ex-Date 24-Jul-2013 Type D Description 1.20/share@12.00% Record Date - Ratio 12.00

Ex-Date 21-Mar-2012 Type R Description /share@5:12% Record Date 23-Mar-2012 Ratio 5:12

Ex-Date 13-Jul-2009 Type D Description 3.50/share@35.00% Record Date - Ratio 35.00

Ex-Date 17-Jul-2008 Type D Description 2.50/share@25.00% Record Date - Ratio 25.00

Ex-Date 11-Jul-2007 Type D Description 2.50/share@25.00% Record Date - Ratio 25.00

Dividends

Announcement Date 18-Jul-2025 Ex Dividend Date 18-Jul-2025 Dividend(%) 120

Announcement Date 12-Jul-2024 Ex Dividend Date 12-Jul-2024 Dividend(%) 140

Announcement Date 11-Jul-2023 Ex Dividend Date 11-Jul-2023 Dividend(%) 100

Announcement Date 14-Jul-2022 Ex Dividend Date 14-Jul-2022 Dividend(%) 50

Announcement Date 29-Jun-2021 Ex Dividend Date 29-Jun-2021 Dividend(%) 30

Announcement Date 10-Nov-2020 Ex Dividend Date 10-Nov-2020 Dividend(%) 20

Announcement Date 18-Feb-2020 Ex Dividend Date 18-Feb-2020 Dividend(%) 20

Announcement Date 27-Jun-2019 Ex Dividend Date 27-Jun-2019 Dividend(%) 12

Announcement Date 04-Aug-2016 Ex Dividend Date 04-Aug-2016 Dividend(%) 20

Announcement Date 06-Aug-2015 Ex Dividend Date 06-Aug-2015 Dividend(%) 15

Announcement Date 16-Jun-2014 Ex Dividend Date 16-Jun-2014 Dividend(%) 15

Announcement Date 16-Jun-2014 Ex Dividend Date 16-Jun-2014 Dividend(%) 15

Announcement Date 24-Jul-2013 Ex Dividend Date 24-Jul-2013 Dividend(%) 12

Announcement Date 13-Jul-2009 Ex Dividend Date 13-Jul-2009 Dividend(%) 35

Announcement Date 17-Jul-2008 Ex Dividend Date 17-Jul-2008 Dividend(%) 25

Announcement Date 11-Jul-2007 Ex Dividend Date 11-Jul-2007 Dividend(%) 25

Bonus

No Bonus has been declared by NEULANDLAB

Splits

No Split has been declared by NEULANDLAB

Others

Ex-Rights Date 13-Aug-2014 Premium(Rs.) 194.00 Ratio 4:25

Ex-Rights Date 21-Mar-2012 Premium(Rs.) 35.00 Ratio 5:12

Neuland Laboratories Ltd Peer Comparison

Shows key financial metrics for the company and its peers

This section compares Neuland Laboratories Ltd with leading peers in the banking sector based on key metrics such as market capitalization, 1-year return, P/E (TTM), and PB ratio. It helps investors evaluate Neuland Laboratories Ltd's relative performance and valuation against major competitors.

Stock Name Cohance Lifesciences Ltd ₹589.30 (+1.28%) M. Cap (Cr) 225.45 1 Yr Return (%) -53.76% P/E (TTM) 90.96 PB Ratio 13.19

Stock Name Astrazeneca Pharma India Ltd ₹8988.00 (-1.59%) M. Cap (Cr) 224.70 1 Yr Return (%) +42.54% P/E (TTM) 112.83 PB Ratio 33.08

Stock Name Wockhardt Ltd ₹1311.30 (-1.04%) M. Cap (Cr) 213.08 1 Yr Return (%) +11.63% P/E (TTM) -926.42 PB Ratio 6.27

Stock Name Neuland Laboratories Ltd ₹16598.00 (-0.72%) M. Cap (Cr) 212.95 1 Yr Return (%) +12.39% P/E (TTM) 88.68 PB Ratio 15.26

Stock Name OneSource Specialty Pharma Ltd ₹1630.40 (-2.51%) M. Cap (Cr) 186.78 1 Yr Return (%) NaN% P/E (TTM) 467.37 PB Ratio 3.18

Stock Name Sai Life Sciences Ltd ₹861.35 (-1.44%) M. Cap (Cr) 181.03 1 Yr Return (%) NaN% P/E (TTM) 63.21 PB Ratio 18.71

Stock Name Alembic Pharmaceuticals Ltd ₹901.00 (+0.17%) M. Cap (Cr) 177.10 1 Yr Return (%) -13.19% P/E (TTM) 27.92 PB Ratio 3.41

Neuland Laboratories Ltd Cash Flow

Cash flow data provides a view of how money is generated and spent by Neuland Laboratories Ltd, across its operating activities, investing activities, and financing activities.

PARTICULARS Operating Activities Mar 2025 317.49 Mar 2024 260.06 Mar 2023 238.53 Mar 2022 58.60 Mar 2021 189.28

PARTICULARS Investing Activities Mar 2025 -298.14 Mar 2024 -149.67 Mar 2023 -61.50 Mar 2022 -93.72 Mar 2021 -84.42

PARTICULARS Financing Activities Mar 2025 24.96 Mar 2024 -69.28 Mar 2023 -135.80 Mar 2022 37.72 Mar 2021 -113.66

PARTICULARS Net Cash Flow Mar 2025 44.31 Mar 2024 41.11 Mar 2023 41.24 Mar 2022 2.60 Mar 2021 -8.80

Neuland Laboratories Ltd Shareholding Pattern

This shows the ownership breakdown of Neuland Laboratories Ltd, highlighting participation from Foreign Institutional Investors (FII), Mutual Funds, Public, Other Institutions, and Promoters.

Promoter 32.64%

Public 32.8%

Other Institutions 4.17%

FII 20.6%

Mutual Funds 9.78%

About Neuland Laboratories Ltd

Incorporated on January 7, 1984, Neuland Laboratories Limited (NLL) is promoted by Davuluri Sucheth Rao. The Company is engaged in manufacturing and selling of bulk drugs such as Salbutamol Sulphate, Terbutaline Sulphate, Labetalol Hydrochloride and Ciprofloxacin. Neuland Drugs & Pharmaceuticals Pvt. Ltd., a company set up by the same promoters to manufacture bulk drugs was merged with the Company effective from April, 1992. NLL manufactures bulk drugs.The Company came out with its initial public offering in Apr.'94 at a premium of Rs 35 aggregating Rs 5.69 cr, to part-finance the capacity expansion to manufacture bulk drugs and to diversify its product-mix. The cost of the project as estimated by ICICI was Rs 15.7 cr.NLL's products are exported to more than 35 countries including Germany, Italy, Switzerland, the UK and the Netherlands. The company is also negotiating with multinational companies for tying up supplies of Ranitidine Hydrochloride Form I and Salbutamol Sulphate.During the year 1999-2000, the company introduced Itraconazole, an anti-fungal drug and Ipratropium Bromide, an anti-asthmatic drug and the R & D has developed a process for manufacture of Oflaxacin for Regulatory Markets. The Pashamylaram unit has received USFDA approval for manufacturing of Rantidine Hydrochloride Form.Mirtrazapine, an anti-depressive drug and Ramipril a cardiovascular drug were introduced during the year 2001.The installed capacities of Ciprofloxacin and Ranitidine were increased with Rs.650 lacs financial assisitance from IDBI.The Company commenced commercial production of Ramipril, a cardiovascular drug for export to certain markets in 2002.The Company commenced commercial production of Citalopram Hydrobromide, an anti depressant, Pirbuterol Acetate, a bronchodilator, Levofloxacin, an anti bacterial, Levetiracetam, an anti convulsant in 2003.A subsidiary company of Neuland Laboratories Ltd was incorporated on January 4, 2007 in the State of Delaware, USA with its principal office in Orange County, California. During the year 2008-2009, Neuland Laboratories K.K., Japan was incorporated as a subsidiary of Company.During 2012-13, Company undertook a major reorganisation of businesses aimed at de-leveraging on one hand and on other hand narrowing the focus on core activities: APIs, Intermediates and Contract Manufacturing. Consequently, the Company divested its R&D activities by selling its Land and Building and some identified intellectual properties to Neuland Pharma Research Private Limited and its Peptides Research activities along with identified intellectual properties to Neuland Health Sciences Private Limited. It entered into a Joint Business Arrangement with API Corporation, Japan, a part of Mitsubishi Chemical, for manufacturing and sale of APIs and Intermediates.During 2013-14, the Company enhanced its product bouquet by launching 5 more products. It also enhanced its development portfolio to 22 molecules/ APIs created for launch between 2013 and 2016. It opened new office in New Jersey, provide them with quick support and coordinate in various business activities.In 2018, the Board of Directors of the Company approved the Scheme of Amalgamation of Neuland Health Sciences Private Limited and Neuland Pharma Research Private Limited with the Company, on April 1, 2016, the Appointed Date of Scheme. Pursuant to the Scheme of Amalgamation, 45,90,608 equity shares held by Neuland Health Sciences Private Limited in the Company were cancelled and the Company allotted 68,61,243 equity shares to the shareholders of Neuland Health Sciences Private Limited and Neuland Pharma Research Private Limited on April 13, 2018 and further 1,675,000 equity shares were issued and allotted under Qualified Institutional Placement (QIP). The Company acquired Advanced Intermediates and API facility Unit 3, with a capacity of about 197 kiloliters at Gaddapotharam Village, in Sanga Reddy District, in 2018-19. The Unit III was commercialised with 320 kL reaction volume in FY 2023.

Executive Chairman

D R Rao

Registered office 11 Th Floor Phoenix IVY Buildi, Plot No 573A-III Road No 82, Hyderabad, Telangana, 500035

FAX :91-40-30211600

Background

Incorporation Year 1984

Face Value ₹10.00

Market Lot 1

Neuland Laboratories Ltd Latest News

VIEW MORE NEWS

FAQs on Neuland Laboratories Ltd